{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T02:28:22Z","timestamp":1791167302761,"version":"4.1.0"},"reference-count":68,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2015,8,1]],"date-time":"2015-08-01T00:00:00Z","timestamp":1438387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,12]],"date-time":"2019-11-12T00:00:00Z","timestamp":1573516800000},"content-version":"vor","delay-in-days":1564,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2015,8]]},"DOI":"10.1093\/annonc\/mdv102","type":"journal-article","created":{"date-parts":[[2015,2,26]],"date-time":"2015-02-26T10:22:27Z","timestamp":1424946147000},"page":"1667-1677","source":"Crossref","is-referenced-by-count":84,"title":["A comprehensive review of lenalidomide therapy for B-cell non-Hodgkin lymphoma"],"prefix":"10.1016","volume":"26","author":[{"given":"T.E.","family":"Witzig","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.S.","family":"Nowakowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.M.","family":"Habermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Goy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.J.","family":"Hernandez-Ilizaliturri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Chiappella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U.","family":"Vitolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Fowler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.S.","family":"Czuczman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdv102_bb0010","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3322\/caac.21208","article-title":"Cancer statistics, 2014","volume":"64","author":"Siegel","year":"2014","journal-title":"CA Cancer J Clin"},{"key":"10.1093\/annonc\/mdv102_bb0015","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/S0140-6736(12)60605-9","article-title":"Non-Hodgkin lymphoma","volume":"380","author":"Shankland","year":"2012","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdv102_bb0020","series-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues,","author":"Swerdlow","year":"2008"},{"key":"10.1093\/annonc\/mdv102_bb0025","unstructured":"NCCN Clinical Practice Guidelines in Oncology: Non-Hodgkin's Lymphomas. v1.2014; http:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/nhl.pdf (6 January 2014, date last accessed)."},{"key":"10.1093\/annonc\/mdv102_bb0030","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial","volume":"381","author":"Rummel","year":"2013","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdv102_bb0035","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1182\/blood-2013-11-531327","article-title":"Randomized trial of bendamustine-rituximab or R-CHOP\/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study","volume":"123","author":"Flinn","year":"2014","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdv102_bb0040","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1182\/blood-2011-09-370320","article-title":"CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe d'Etude des Lymphomes de l'Adulte","volume":"121","author":"Delarue","year":"2013","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdv102_bb0045","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJMoa1200920","article-title":"Treatment of older patients with mantle-cell lymphoma","volume":"367","author":"Kluin-Nelemans","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdv102_bb0050","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.3109\/10428194.2011.570396","article-title":"Treatment recommendations for radioimmunotherapy in follicular lymphoma: a consensus conference report","volume":"52","author":"Witzig","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"10.1093\/annonc\/mdv102_bb0055","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/sj.leu.2402745","article-title":"Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo","volume":"17","author":"Lentzsch","year":"2003","journal-title":"Leukemia"},{"key":"10.1093\/annonc\/mdv102_bb0060","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1182\/blood-2005-10-4184","article-title":"Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications","volume":"108","author":"Chang","year":"2006","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdv102_bb0065","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.leukres.2006.01.010","article-title":"Lenalidomide inhibits proliferation of Namalwa CSN.70 cells and interferes with Gab1 phosphorylation and adaptor protein complex assembly","volume":"30","author":"Gandhi","year":"2006","journal-title":"Leuk Res"},{"key":"10.1093\/annonc\/mdv102_bb0070","doi-asserted-by":"crossref","first-page":"6250","DOI":"10.1073\/pnas.0901166106","article-title":"E(mu)-TCL1 mice represent a model for immunotherapeutic reversal of chronic lymphocytic leukemia-induced T-cell dysfunction","volume":"106","author":"Gorgun","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1093\/annonc\/mdv102_bb0075","doi-asserted-by":"crossref","first-page":"4713","DOI":"10.1182\/blood-2009-04-217687","article-title":"Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy","volume":"114","author":"Ramsay","year":"2009","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdv102_bb0080","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1158\/0008-5472.CAN-06-2317","article-title":"Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells","volume":"67","author":"Verhelle","year":"2007","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdv102_bb0085","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1002\/ajh.21468","article-title":"Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo","volume":"84","author":"Zhang","year":"2009","journal-title":"Am J Hematol"},{"key":"10.1093\/annonc\/mdv102_bb0090","doi-asserted-by":"crossref","first-page":"4650","DOI":"10.1158\/1078-0432.CCR-07-4405","article-title":"Lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells","volume":"14","author":"Wu","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdv102_bb0095","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1053\/j.seminhematol.2005.10.001","article-title":"Lenalidomide and thalidomide: mechanisms of action\u2014similarities and differences","volume":"42","author":"Anderson","year":"2005","journal-title":"Semin Hematol"},{"key":"10.1093\/annonc\/mdv102_bb0100","doi-asserted-by":"crossref","first-page":"181","DOI":"10.2174\/1568008033340207","article-title":"Thalidomide derived immunomodulatory drugs (IMiDs) as potential therapeutic agents","volume":"3","author":"Marriott","year":"2003","journal-title":"Curr Drug Targets Immune Endocr Metabol Disord"},{"key":"10.1093\/annonc\/mdv102_bb0105","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.leukres.2010.09.027","article-title":"Lenalidomide synergizes with dexamethasone to induce growth arrest and apoptosis of mantle cell lymphoma cells in vitro and in vivo","volume":"35","author":"Qian","year":"2011","journal-title":"Leuk Res"},{"key":"10.1093\/annonc\/mdv102_bb0110","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/bjh.12172","article-title":"Lenalidomide efficacy in activated B-cell-like subtype diffuse large B-cell lymphoma is dependent upon IRF4 and cereblon expression","volume":"160","author":"Zhang","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1093\/annonc\/mdv102_bb0115","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.ccr.2012.05.024","article-title":"Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma","volume":"21","author":"Yang","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1093\/annonc\/mdv102_bb0120","unstructured":"REVLIMID (lenalidomide) capsules, for oral use prescribing information. Summit (NJ): Celgene Corporation 2013."},{"key":"10.1093\/annonc\/mdv102_bb0125","doi-asserted-by":"crossref","first-page":"5404","DOI":"10.1200\/JCO.2008.21.1169","article-title":"Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's Lymphoma","volume":"27","author":"Witzig","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdv102_bb0130","doi-asserted-by":"crossref","first-page":"4952","DOI":"10.1200\/JCO.2007.15.3429","article-title":"Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma","volume":"26","author":"Wiernik","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdv102_bb0135","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/j.1365-2141.2009.07626.x","article-title":"Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma","volume":"145","author":"Habermann","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1093\/annonc\/mdv102_bb0140","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1093\/annonc\/mdq626","article-title":"An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma","volume":"22","author":"Witzig","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdv102_bb0145","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1093\/annonc\/mdt366","article-title":"Long-term follow-up of lenalidomide in relapsed\/refractory mantle cell lymphoma: subset analysis of the NHL-003 study","volume":"24","author":"Zinzani","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdv102_bb0150","doi-asserted-by":"crossref","first-page":"3688","DOI":"10.1200\/JCO.2013.49.2835","article-title":"Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study","volume":"31","author":"Goy","year":"2013","journal-title":"J Clin Oncol"},{"issue":"suppl","key":"10.1093\/annonc\/mdv102_bb0155","article-title":"Combined analysis of single-agent lenalidomide in relapsed\/refractory mantle cell lymphoma","volume":"31","author":"Witzig","year":"2013","journal-title":"J Clin Oncol"},{"issue":"suppl","key":"10.1093\/annonc\/mdv102_bb0160","article-title":"Single-agent lenalidomide in relapsed\/refractory mantle cell lymphoma: a combined analysis from the MCL-001, NHL-002, and NHL-003 studies","volume":"98","author":"Witzig","year":"2013","journal-title":"Haematologica"},{"issue":"suppl 2;","key":"10.1093\/annonc\/mdv102_bb0165","article-title":"Lenalidomide monotherapy is clinically active in patients with relapsed\/refractory diffuse large B-cell lymphoma (DLBCL): a pooled analysis of data from phase II studies (NHL-002\/003)","volume":"95","author":"Czuczman","year":"2010","journal-title":"Haematologica"},{"key":"10.1093\/annonc\/mdv102_bb0170","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/bjh.12008","article-title":"Single-agent lenalidomide in relapsed\/refractory mantle cell lymphoma: results from a UK phase II study suggest activity and possible gender differences","volume":"159","author":"Eve","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1093\/annonc\/mdv102_bb0175","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1111\/bjh.12449","article-title":"Single-agent lenalidomide is active in patients with relapsed or refractory aggressive non-Hodgkin lymphoma who received prior stem cell transplantation","volume":"162","author":"Vose","year":"2013","journal-title":"Br J Haematol"},{"issue":"suppl","key":"10.1093\/annonc\/mdv102_bb0180","article-title":"Lenalidomide in relapsed\/refractory mantle cell lymphoma post-bortezomib: subgroup analysis of the MCL-001 study","volume":"31","author":"Williams","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdv102_bb0185","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V122.21.3057.3057","article-title":"Updated efficacy and safety, and exploratory Ki-67 results for the MCL-001 study of lenalidomide in mantle cell lymphoma patients who relapsed or were refractory to bortezomib","volume":"122","author":"Goy","year":"2013","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdv102_bb0190","doi-asserted-by":"crossref","first-page":"5058","DOI":"10.1002\/cncr.26135","article-title":"Higher response to lenalidomide in relapsed\/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype","volume":"117","author":"Hernandez-Ilizaliturri","year":"2011","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdv102_bb0195","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V120.21.3694.3694","article-title":"Lenalidomide is effective in heavily pretreated non-Hodgkin lymphoma (NHL): analysis of a retrospective data collection","volume":"120","author":"Rigacci","year":"2012","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdv102_bb0200","doi-asserted-by":"crossref","first-page":"5984","DOI":"10.1158\/1078-0432.CCR-05-0577","article-title":"Immunomodulatory drug CC-5013 or CC-4047 and rituximab enhance antitumor activity in a severe combined immunodeficient mouse lymphoma model","volume":"11","author":"Hernandez-Ilizaliturri","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdv102_bb0205","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/j.1365-2141.2007.06841.x","article-title":"Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo","volume":"140","author":"Reddy","year":"2008","journal-title":"Br J Haematol"},{"key":"10.1093\/annonc\/mdv102_bb0210","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/S1470-2045(12)70200-0","article-title":"Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1\/2 clinical trial","volume":"13","author":"Wang","year":"2012","journal-title":"Lancet Oncol"},{"issue":"21","key":"10.1093\/annonc\/mdv102_bb0215","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.625.625","article-title":"Sustained remission with the combination biologic doublet of lenalidomide plus rituximab as initial treatment for mantle cell lymphoma: a multicenter phase II study report","volume":"124","author":"Ruan","year":"2014","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdv102_bb0220","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1038\/leu.2013.95","article-title":"Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial","volume":"27","author":"Wang","year":"2013","journal-title":"Leukemia"},{"key":"10.1093\/annonc\/mdv102_bb0225","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.clml.2011.02.001","article-title":"Combination of lenalidomide and rituximab in elderly patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 2 trial","volume":"11","author":"Zinzani","year":"2011","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1093\/annonc\/mdv102_bb0230","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1002\/hon.2049","article-title":"Long-term efficacy of the combination of lenalidomide and rituximab in elderly relapsed\/refractory diffuse large B-cell lymphoma patients","volume":"31","author":"Zinzani","year":"2013","journal-title":"Hematol Oncol"},{"key":"10.1093\/annonc\/mdv102_bb0235","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/bjh.12755","article-title":"Lenalidomide plus rituximab can produce durable clinical responses in patients with relapsed or refractory, indolent non-Hodgkin lymphoma","volume":"165","author":"Tuscano","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1093\/annonc\/mdv102_bb0240","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2012.30.15_suppl.8000","article-title":"CALGB 50401: a randomized trial of lenalidomide alone versus lenalidomide plus rituximab in patients with recurrent follicular lymphoma","volume":"30","author":"Leonard","year":"2012","journal-title":"J Clin Oncol"},{"issue":"suppl I","key":"10.1093\/annonc\/mdv102_bb0245","article-title":"CALGB 50803(ALLIANCE): a phase 2 trial of lenalidomide plus rituximab in patients with previously untreated follicular lymphoma","volume":"31","author":"Martin","year":"2013","journal-title":"Hematol Oncol"},{"key":"10.1093\/annonc\/mdv102_bb0250","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/S1470-2045(14)70455-3","article-title":"Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial","volume":"15","author":"Fowler","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdv102_bb0255","doi-asserted-by":"crossref","first-page":"416","DOI":"10.3324\/haematol.2011.051813","article-title":"Salvage treatment with lenalidomide and dexamethasone in relapsed\/refractory mantle cell lymphoma: clinical results and effects on microenvironment and neo-angiogenic biomarkers","volume":"97","author":"Zaja","year":"2012","journal-title":"Haematologica"},{"key":"10.1093\/annonc\/mdv102_bb0260","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/cncr.28405","article-title":"Combined lenalidomide, low-dose dexamethasone, and rituximab achieves durable responses in rituximab-resistant indolent and mantle cell lymphomas","volume":"120","author":"Ahmadi","year":"2014","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdv102_bb0265","first-page":"1","article-title":"Therapy with bortezomib plus lenalidomide for relapsed\/refractory mantle cell lymphoma: Final results of a phase II trial (CALGB 50501)","author":"Morrison","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"10.1093\/annonc\/mdv102_bb0270","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V120.21.2748.2748","article-title":"Rituximab, lenalidomide, and bortezomib in the first-line or second-line treatment of patients with mantle cell lymphoma: a phase I\/II trial","volume":"120","author":"Flinn","year":"2012","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdv102_bb0275","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1200\/JCO.2014.55.5714","article-title":"Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-cell lymphoma: a phase II study","volume":"33","author":"Nowakowski","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdv102_bb0280","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V122.21.248.248","article-title":"Lenalidomide in combination with R-CHOP (R2-CHOP) in patients with high burden follicular lymphoma: Phase 2 study","volume":"122","author":"Tilly","year":"2013","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdv102_bb0285","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/S1470-2045(14)70191-3","article-title":"Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial","volume":"15","author":"Vitolo","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdv102_bb0290","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V122.21.4377.4377","article-title":"Lenalidomide, bendamustine, and rituximab as first-line therapy for patients >65 years with mantle cell lymphoma: preliminary results from the Nordic Lymphoma Group MCL4 (LENA-BERIT) phase I-II trial","volume":"122","author":"Jerkeman","year":"2013","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdv102_bb0295","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa070594","article-title":"Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma","volume":"357","author":"Dimopoulos","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdv102_bb0300","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1056\/NEJMoa070596","article-title":"Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America","volume":"357","author":"Weber","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdv102_bb0305","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1007\/s00277-012-1490-6","article-title":"Combination of low doses of enzastaurin and lenalidomide has synergistic activity in B-non-Hodgkin lymphoma cell lines","volume":"91","author":"Cosenza","year":"2012","journal-title":"Ann Hematol"},{"key":"10.1093\/annonc\/mdv102_bb0310","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1038\/leu.2011.165","article-title":"Lenalidomide can be safely combined with R-CHOP (R2CHOP) in the initial chemotherapy for aggressive B-cell lymphomas: phase I study","volume":"25","author":"Nowakowski","year":"2011","journal-title":"Leukemia"},{"key":"10.1093\/annonc\/mdv102_bb0315","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/leu.2012.172","article-title":"Phase 1b study of lenalidomide in combination with rituximab-CHOP (R2-CHOP) in patients with B-cell lymphoma","volume":"27","author":"Tilly","year":"2013","journal-title":"Leukemia"},{"key":"10.1093\/annonc\/mdv102_bb0320","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.3324\/haematol.2013.085134","article-title":"Lenalidomide plus cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab is safe and effective in untreated, elderly patients with diffuse large B-cell lymphoma: a phase I study by the Fondazione Italiana Linfomi","volume":"98","author":"Chiappella","year":"2013","journal-title":"Haematologica"},{"key":"10.1093\/annonc\/mdv102_bb0325","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1007\/s00277-013-1751-z","article-title":"Rituximab, bendamustine, and lenalidomide in patients with aggressive B cell lymphoma not eligible for high-dose chemotherapy or anthracycline-based therapy: phase I results of the SAKK 38\/08 trial","volume":"92","author":"Hitz","year":"2013","journal-title":"Ann Hematol"},{"key":"10.1093\/annonc\/mdv102_bb0330","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V118.21.2700.2700","article-title":"Lenalidomide, bendamustine, and rituximab as first-line therapy for patients >65 years with mantle cell lymphoma: results from the phase I portion of the Nordic Lymphoma Group MCL4 (LENA-BERIT) trial","volume":"118","author":"Jerkeman","year":"2011","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdv102_bb0335","unstructured":"N Howlader AM Noone M Krapcho (eds). SEER Cancer Statistics Review, 1975\u20132007. Bethesda, MD: National Cancer Institute 2015. http:\/\/seer.cancer.gov\/csr\/1975_2011\/, based on November 2013 SEER data submission, posted to the SEER website, April 2014."},{"key":"10.1093\/annonc\/mdv102_bb0340","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.3109\/10428194.2011.573031","article-title":"Lenalidomide monotherapy for relapsed\/refractory peripheral T-cell lymphoma not otherwise specified","volume":"52","author":"Zinzani","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"10.1093\/annonc\/mdv102_bb0345","doi-asserted-by":"crossref","first-page":"5119","DOI":"10.1182\/blood-2011-07-362475","article-title":"A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma","volume":"118","author":"Fehniger","year":"2011","journal-title":"Blood"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419318332?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419318332?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/26\/8\/1667\/5025595\/mdv102.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,7]],"date-time":"2024-06-07T12:19:21Z","timestamp":1717762761000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419318332"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8]]},"references-count":68,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2015,8]]}},"alternative-id":["S0923753419318332"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdv102","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2015,8]]}}}